Advanced search×

Coronary artery calcium score improves cardiovascular risk prediction in persons without indication for statin therapy

Atherosclerosis 215(1):8 (2011) PMID 21251655

Background: Recent revision to the Canadian Cardiovascular Society (CCS) guidelines on cardiovascular disease (CVD) risk stratification provides expanded recommendations for statin therapy. If CVD risk in the remaining individuals can further be stratified and discriminated by additional risk assessment using coronary artery calcium (CAC) scoring is unknown. Methods and results: In a retrospectively analyzed subgroup comprising 1934 participants from the Heinz Nixdorf Recall study, who did not meet criteria for statin therapy based on current CCS guidelines, traditional CVD risk variables and CAC were measured. Between 2000 and 2008, incident CVD events, i.e. coronary deaths, non-fatal myocardial infarction, coronary revascularization, stroke and CV death were determined. Those 43 participants who experienced 55 CVD events (5-year risk to first event: 2.2% (1.6-3.0%)) had higher CAC scores than those who did not (p10% was 25.1%, p=0.01, largely driven by a 32.6% correct up-classification in persons with events. Yet, only 38 (2%) of participants were identified being at high risk using CAC imaging in addition to traditional risk factor assessment. Conclusion: Adding CAC to traditional risk assessment in persons without indication for statin therapy improves discrimination. However, reclassification to the high risk category and overall event rates seem too low to justify liberal CAC testing in all these individuals.

DOI: 10.1016/j.atherosclerosis.2010.12.014
Version: za2963e q8zab q8zbd q8zcf q8zd3 q8ze0 q8zf0 q8zgc

Similar articles you may find interesting…

  1. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates.

    Epidemiology 11(2):167-70 (2000) PMID 11021614

    We document a decrease in U.S. prostate cancer mortality rates in white men less than 85 years of age to levels below those existing in 1986, the year use of PSA testing was approved. In fact, for men 60-79 years of age, prostate cancer mortality rates were lower in 1997 than in any year since 1950....
  2. Insights from the conduct of a device trial in older persons: low magnitude mechanical stimulation for musculoskeletal health.

    Clin Trials 7(4):354-67 (2010) PMID 20571129

    These lessons will guide future investigations in studies of individuals of advanced age....